Answers are grounded in this paper and cite their sources.
Retrospective review finds improved urinary flow following tamsulosin dose escalation in men with benign prostatic hyperplasia, highlighting clinical value for inadequate lower-dose responses.
PURPOSE: This study evaluated the clinical impact of escalating tamsulosin dosage from 0.2 to 0.4 mg in men with benign prostatic hyperplasia (BPH) who exhibited inadequate responses to the lower dose. MATERIALS AND METHODS: A retrospective review was performed on 57 patients treated at Seoul National University Bundang Hospital in 2022. Uroflowmetry parameters, International Prostate Symptom Score (IPSS), and postvoid residual volume (PVR) were compared before and after dose escalation. Subgroup analysis was conducted by age, prostate volume, and concomitant 5-alpha-reductase inhibitor use. RESULTS: The mean maximum urinary flow rate value improved significantly from 14.4 to 17.7 mL/s (p<0.001), with consistent benefits across subgroups. No significant changes were observed in IPSS or PVR overall, although PVR decreases were significant in prostates >50 mL. CONCLUSIONS: Escalating tamsulosin from 0.2 to 0.4 mg can meaningfully improve urinary flow in certain BPH patients, particularly those with larger prostates or concomitant 5-alpha-reductase inhibitor therapy.
No takes yet. Share an insight, caveat, or question.
Chung et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: